The Uromigos

Health EN ↓ 485 episodes

Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Be sure to visit the podcast's website and support the creator: www.uromigos.org

Author

The Uromigos

Episodes

Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands 29.03.2025 30:29

Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.

Episode 400: The Uromigos Score for Urothelial Cancer 28.03.2025 20:19

Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.

Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers? 24.03.2025 36:44

Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU 17.03.2025 32:05

Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.

Episode 397: APCCC Diagnostics Conference recap 10.03.2025 43:15

Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025 01.03.2025 30:27

Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)

Episode 393: ASCO GU 2025 Review Podcast 26.02.2025 46:06

Silke joins Tom and Brian to discuss highlights form ASCO GU 2025

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC 15.02.2025 30:09

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214 15.02.2025 23:28

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update 15.02.2025 30:03

Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data

Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer 15.02.2025 25:28

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results 14.02.2025 27:07

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.

Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes 14.02.2025 28:23

Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.

Episode 386: ASCO GU 2025 - APRI Meta-analysis 13.02.2025 28:58

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2

Episode 385: ASCO GU 2025 - TALAPRO-2 13.02.2025 32:01

Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data

Episode 384: ASCO GU Preview 06.02.2025 35:23

Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.

Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC 05.02.2025 33:11

David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine

Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade 27.01.2025 40:05

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

Episode 380: The Role of SBRT in RCC 13.01.2025 42:02

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

Episode 378: 2025 Preview of Important GU Data 06.01.2025 41:42

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer

Episode 375: Renal Cancer 2024 Highlights 23.12.2024 43:11

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

Episode 376: Bladder Cancer 2024 Highlights 23.12.2024 25:37

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

Episode 377: Prostate Cancer 2024 Highlights 23.12.2024 35:12

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.

Episode 374: Mechanisms of HIF Resistance 18.12.2024 34:37

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

Episode 372: FDA Accelerated Approval Process 09.12.2024 31:30

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.